Clinical Trial

Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome

Study acronym: CASSPER
Recruiting
View on ClinicalTrials.gov →
Summary
Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder stemming from genetic damage in the 15q11-q13 region, leading to hypothalamic dysfunction. Individuals with PWS often exhibit social interaction challenges, intellectual deficits, significant eating disorders, mood disturbances, and sensory-related autistic features. Although PWS is recognized by DSM-5 as a genetic cause of Autism Spectrum Disorder (ASD), ASD diagnosis in PWS remains rare in France. The CASSPER study aims to investigate the distinct autistic and sensory profiles in children with PWS, also analyzing the potential impact of early oxytocin treatment on these manifestations, in line with recommendations for early and tailored intervention.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-10.
Status change: Not Yet Recruiting → Recruiting 2025-05-05
Trial Details
NCT Number NCT06877715
Lead Sponsor University Hospital, Toulouse
Conditions Prader-Willi Syndrome
Enrollment 75 participants
Start Date 2025-04-07
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-08